| Assessment Status | Rapid review complete |
| HTA ID | - |
| Drug | Velaglucerase Alfa |
| Brand | VPRIV® |
| Indication | For long-term enzyme replacement therapy (ERT) in patients with type1 Gaucher disease. |
| Assessment Process | |
| Rapid review commissioned | 26/04/2011 |
| Rapid review completed | 20/06/2011 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended. |
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.